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Abstract. The use of nitazoxanide has previously yielded 
successful results in vitro against the coronavirus. The aim 
of the present study was to examine the efficacy of the use 
of nitazoxanide at an early stage among healthcare workers 
exhibiting symptoms of COVID‑19. This was a prospective 
study carried out in 2020. Healthcare personnel who presented 
with COVID‑19 symptoms, in different 3 hospitals were invited 
to take Paramix (nitazoxanide), 500 mg orally, every 6 h for 
2 days and then 500 mg twice a day for 4 days. To compare the 
hospitalization percentage, a group of healthcare workers with 
a respiratory viral infection without COVID‑19 criteria were 
also followed‑up. Over a period of 3 months, 150 healthcare 
workers (111 women and 39 men) presented respiratory symp‑
toms with COVID‑19 criteria (mean age, 36±10.6 years; range, 
18‑68 years). Only one female medical doctor, one nurse and 
one male from the auxiliary services had to be hospitalized and 
one death was registered It was thus concluded that nitazoxanide 
yielded successful results in vitro against previous coronavirus 
and may prove to be useful against SARS‑CoV‑2 as an early 
intervention to avoid complications, decreasing the expected 
number of hospitalizations among infected healthcare workers.
Introduction
The pandemic caused by the Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS‑CoV‑2; COVID‑19) is the 
most severe one faced by humans over the past 100 years. 
The number of confirmed cases worldwide has exceeded 
100 million with the total number of related deaths close to 
two and a half a million (as of February 10, 2021) (1).
In Mexico, since the first cases were reported in Mexico 
City and Sinaloa on February 28, 2020, and with the 
antecedent in both areas having traveled to the Lombardy 
region in Italy prior to the onset of symptoms (2) and to date 
February 10, 2021, there have been 1,936,013 confirmed cases 
with 166,731 deaths.
Healthcare personnel have the potential for direct or indirect 
exposure to patients or infectious materials (3). Unfortunately, 
these essential workers fighting the coronavirus pandemic are 
becoming infected and many succumb to the disease; in the 
case of Mexico, 20% of all infected individuals in the country 
are professionals in the health sector (4). Exemplifying the 
critical situation of this group, during the daily national 
conference of the pandemic evolution on June 23, 2020, it was 
stated that of the ~200,000 workers in the healthcare system, 
39,032 were COVID‑19‑positive with 584 deaths noted (5). As 
previously stated, it is necessary to protect healthcare profes‑
sionals (6), not only with strict infection‑control measures (7) 
and proper equipment (8), but also by offering early treatment 
options to reduce the length of infectiousness.
It has been well‑established that the exposure of profes‑
sionals to patients diagnosed with COVID‑19 can lead to 
different clinical outcomes (9). In Mexico, the possibility of 
determining with precision whether the medical doctor, nurse 
or healthcare worker has contracted COVID‑19 in a specific 
hospital is more difficult, as these workers frequently work in 
>1 institution (10).
Conversely, amongst the realistic options available for the 
treatment of COVID‑19, nitazoxanide is a low‑cost drug and its 
circulating active metabolite, tizoxanide, inhibits both RNA and 
DNA viral replication, exhibiting action against influenza A, 
respiratory syncytial virus, norovirus, dengue, yellow fever, 
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Japanese encephalitis virus, rotavirus, hepatitis B and C, human 
immunodeficiency virus, SARS and Middle East Respiratory 
Syndrome, the latter two of which are also coronaviruses (11,12).
The aim of the present study was to demonstrate the effec‑
tiveness of prescribing nitazoxanide to healthcare workers 
from the initiation of COVID‑19 symptoms in order to reduce 
the number of hospitalizations, as well as the proportion of 
COVID‑19‑associated fatalities.
Patients and methods
Study design. The present study was a prospective study that 
was conducted between May 1st and July 20th 2020, and 
included 3 hospitals of the Health Institute of the State of 
Mexico: ‘Mónica Pretelini Sáenz’ Maternal‑Perinatal Hospital 
(HMPMPS), located in Toluca, Mexico; Hospital General de 
Axapusco (Axapusco, State of Mexico); and Hospital General 
de Cuautitlán ‘José Vicente Villada’, Cuautitlán, State of 
Mexico, Mexico.
The present study was approved by the Research Ethics 
Committee of HMPMPS (approval no. 2020‑04‑682), and was 
performed in accordance with the ethical guidelines described 
in the Helsinki Declaration (Fortaleza, Brazil, 2013).
Patients. The healthcare personnel who presented with 
COVID‑19 symptoms were invited to take Paramix (nitazoxanide) 
(Laboratorios Liomont, S.A. de C.V.), 500 mg orally every 6 h for 
2 days, and then 500 mg twice a day for 4 days. The proposed 
dose was based on preprint research by Padmanabhan (13,14). In 
the case of fever, 500 mg paracetamol every 8 h were adminis‑
tered. As regards sample size, the following formula was used for 
population calculations:
where Zα = 1.645, p = the percentage of patients with 
COVID‑19 requiring hospitalization (30%), d = allowed error 
(5%), no = number of healthcare workers with COVID‑19 that 
required treatment in the present study to be representative of 
the community (n=227).
Knowing the limit of the population, healthcare personnel 
who presented a direct risk to patients with COVID‑19, 
excluding those without contact with patients, those who were 
sent home for being at risk of contracting COVID (>65 years 
of age or with comorbidities), those specialists whose attention 
was cancelled due to the Hospital conversion into an exclusive 
COVID health center, added to the decision of administra‑
tive work by guards and staff who quit their job, n=445, the 
following formula was used:
and the sample (n) was representative of the healthcare work 
force at risk, which was 150 healthcare workers.
Procedure. In HMPMPS, once a healthcare personnel presented 
with COVID‑19 symptoms, they were sent to be evaluated by 
the Epidemiology Service, and if consistent with SARS‑CoV‑2 
infection, the worker was then sent to the Research Unit to 
receive a medical prescription. The procedure in the other two 
hospitals was to name a medical doctor to be in charge of the 
evaluation and prescription of nitazoxanide.
The drugs were distributed using Soluglob Ikon S.A. de C.V., 
which offers an automated process for individualized doses 
of every drug. The affected worker had to go to the Soluglob 
Pharmacy of their hospital to receive the drug dose after completing 
the informed consent form that included a semaphore‑type scale 
of symptoms (Table I). The personal data collected from each 
participant included the following: Address, telephone and cell 
phone number to allow follow‑up for pharmacovigilance.
A quantitative PCR test to confirm infection with 
COVID‑19 was performed at the Public Health Laboratory of 
the State of Mexico. Other studies that were made according 
to the clinical status of each worker were blood biometry, chest 
radiography and computed tomography (CT).
The mobile phones of two Internal Medicine physicians 
were shared with the healthcare workers of the HMPMPS, 
and the same process was replicated by providing the mobile 
number of one Internal Medicine physician in the other hospitals 
(Axapusco and Cuautitlán), to carry out a telephone follow‑up 
and to implement additional/new measures if necessary.
Statistical analysis. Qualitative variables are represented in 
percentages and the quantitative variables are presented as 
the means ± standard deviation using Microsoft Excel 2013 
(Microsoft Corporation). Differences between females and 
males in age and severity were analyzed using a Student's t‑test, 
and a χ2 test was used to compare categorical variables between 
both groups. All the calculated P‑values were two‑tailed. A 
value of P<0.05 was considered to indicate a statistically signif‑
icant difference. Statistical analysis was performed using the 
Social Science Statistics online program (socscistatistics.com).
Results
Sociodemographic characteristics. Over a period of 3 months, 
from May to July, 2020, 150 healthcare workers (mean age, 
36±10.6 years; age range, 18‑68 years), including 111 females 
and 39 males, presented with respiratory symptoms that 
met the COVID‑19 criteria. Only 1 female medical doctor, 
Table I. Semaphore‑type scale of COVID‑19 symptoms.
Symptoms Points
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1 nurse and 1 male worker in the Auxiliary Services had to 
be hospitalized, and unfortunately the male nurse (aged 35) 
passed away. He had obesity grade I, according to the clas‑
sification of the National Institutes of Health (NIH) (15) and 
his wife and in‑laws also became ill; his mother‑in‑law also 
passed away. Eventually, qPCR was performed in 115 health‑
care workers, confirming the diagnosis of COVID‑19; in the 
remaining 35 patients, the characteristic lung lesions caused 
by SARS‑CoV‑2 were determined by a CT scan.
Outcomes. The mean score in the semaphore‑type scale just 
prior to the commencement of the nitazoxanide administration 
was 16±9.8 points; as a whole, the most common presenting 
symptoms were headache (90%), sore throat (62.67%) and 
myalgias (59.33%). Between the sexes, no significant differ‑
ences were observed in age (t‑value, ‑1.2085; P=0.228984), or 
in disease severity (t‑value, 1.05579; P=0.292786). Based on 
the results of the χ2 test, there were no significant differences 
in the severity of any of the symptoms assessed (Table II).
As regards adverse outcomes, 47 (31.33%) subjects 
(39 females and 8 males) reported 61 adverse reactions as 
follows: Gastrointestinal disorders, 51 (34%); renal and urinary 
disorders, 7 (4.66%); nervous system disorders, 1 (0.66%); 
cardiac disorders, 1 (0.66%); and one case with unspecific 
symptoms (anxiety as symptomatology) (Table III).
The most commonly used supplementary medicines 
were the following: Paracetamol, 150 (100%); levofloxacin, 
80 (53.33%); and azithromycin, 25 (16.66%) (Table IV). A CT 
scan revealed severe lung lesions in 3 cases, and one of these 
patients required hospitalization. A second case with affected 
lungs and a persistent fever was treated with meropenem at 
home with a personal nurse.
Discussion
A previous study demonstrated that the majority of the health‑
care workers with confirmed COVID‑19 infections were mild 
cases (16). In another study on healthcare workers, 90% of 
the affected individuals were not hospitalized; however, they 
registered 27 deaths, occurring across all age groups; most 
commonly in those aged ≥65 years (6).
Hospital COVID‑19 outbreaks, with several deaths amongst 
medical doctors, nurses, stretcher handlers, chemists, social 
workers and administrative staff (17‑20), highlight the need for 
Table II. General characteristics of the healthcare workers with COVID‑19.
 Total population Females Males
Variable (n=150) (%) (n=111) (%) (n=39) (%) P‑value
Age (years)   36±10.6   35.2±10   37.7±12.3 0.2289
Semaphore‑type scale (points) 16±9.8 16.5±1 14.6±8.9 0.2927
Fever, ≥38˚C  44.00 41.44 56.41 0.1062
Dry cough 52.67 56.76 48.72 0.3856
Headache 90.00 95.50 87.18 0.0732
Dyspnea 15.33 17.12 10.26 0.3063
Arthralgias 55.33 59.46 51.28 0.3744
Myalgias 59.33 63.96 53.85 0.2643
Sore throat 62.67 66.67 66.67 Not significant
Nose discharge 38.67 44.14 33.33 0.2382
Conjunctivitis 18.00 18.02 17.95 0.9922
Chest pain 38.00 37.84 43.59 0.5270
Diarrhea 36.00 33.33 46.15 0.1529
Anosmia 14.00 12.61 17.95 0.4087
Ageusia 11.33 9.91 15.38 0.3535




Adverse outcome Females Males P‑value
Gastrointestinal disorders   43 8 0.0387
(nausea, vomiting,  
diarrhea, and abdominal pain)
Renal and urinary disorders   4 3 0.2977
Nervous system disorders   1 0 0.5520
(insomnia)
Cardiac disorders (tachycardia)   0 1 0.0905
Unspecific symptoms    1 0 0.5520




Antibiotic Females Males P‑value
Levofloxacin  55 25 0.1170
Azithromycin 18   7 0.8027
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the management and prevention of further breakouts prior to 
the acquisition and widespread availability of a vaccine. The 
study by Wu et al (21) suggested that early antiviral treatment 
significantly attenuated the progression of COVID‑19 and 
improved the prognosis of patients, although some concerns 
limited the applicability of the results of that study (21).
Other studies have demonstrated significant major outpatient 
treatment efficacy with the use of hydroxychloroquine alone or 
of hydroxychloroquine + azithromycin (22). Despite the initial 
enthusiasm regarding hydroxychloroquine (23), given some major 
concerns regarding its use and the validity of these early results, 
there is now strong advice against its use (24,25), increasing the 
need for studies examining other possible therapeutic options.
Yu et al (26) enrolled 129 patients with confirmed 
COVID‑19 (mild to moderate case) who were divided into the 
early or late antiviral treatment groups. The antiviral drugs, 
arbidol, interferon, oseltamivir, ribavirin and ganciclovir, were 
used for the treatment of these patients (26). They concluded 
that early antiviral treatment could effectively shorten the viral 
clearance time and prevent the rapid progression of COVID‑19. 
However, a significant difference was observed in the use of 
glucocorticoids (28.79 vs. 14.29%) between patients with early 
antiviral treatment and those with late treatment (26).
Specific studies regarding prophylactic measures to manage 
COVID‑19 infections have included Abelson kinase inhibitors 
(in vitro) (27), azithromycin (early use at first signs of infection 
in adults and children) (28) and cyclosporin A (in vitro) (29); 
however, in vivo and among healthcare personnel, hydroxy‑
chloroquine has been the most widely evaluated (30). With 
nitazoxanide, positive results were demonstrated in a phase 
2b/3 study for the outpatient management of influenza, in 
which a 600 mg oral dose b.i.d. of nitazoxanide was associated 
with a ~1‑day improvement in time to resolution of symptoms 
compared with the placebo group (31).
The approach employed in the present study differs 
from that of previous studies where they have attempted to 
treat asymptomatic patients, resulting in controversial results 
(clinical symptoms vs. viral clearance). Some researchers have 
supported the notion that antiviral therapy may hasten viral 
clearance in asymptomatic infections (32).
In the present study, a favorable response to nitazoxanide 
was observed with regards to fewer hospitalizations, 
evidencing the benefits of this drug; thus, it was decided to 
implement this regimen as standard treatment for all workers 
with COVID‑19 symptoms, without waiting for the original 
date on which the present study was aimed to reach comple‑
tion (December, 2020), in order to avoid further losses within 
the healthcare sectors in hospitals.
As regards the prescribed drug, an epidemiological surveil‑
lance strategy was deployed, including e‑mails, personal 
supervision at the hospital and telephone follow‑up. No 
suspected cases of glucose‑6‑phosphate dehydrogenase (G6PD) 
deficiency were identified amont those taking paracetamol.
Rocco et al tested early nitazoxanide therapy against 
COVID‑19, confirming a significant viral load reduction (33). 
Although in their study, symptom resolution did not differ between 
the nitazoxanide and placebo groups after 5 days of therapy, the 
prescribed posology was lower than that proposed to achieve the 
minimum inhibitory concentration against SARS‑CoV‑2 (13,14). 
Novel approaches to regimens with nitazoxanide have included 
azithromycin mainly (34,35); however, possible synergistic 
effects with immunomodulants and other types of drugs have 
also been raised (36,37). In the present study, there were no differ‑
ences in surveillance adding either azithromycin or levofloxacin. 
Furthermore, ongoing research has added atazanavir/ritonavir 
for the treatment of moderate to severe COVID‑19 (38) and a 
number of researchers have indicated that nitazoxanide cannot be 
ignored as a valid alternative in the current pandemic (39,40,41).
A handicap that the healthcare forces face in Mexico is 
that the majority of workers do not have social security and 
work without any types of benefits, and numerous individuals 
work on temporary contracts. Thus, if healthcare workers are 
required to isolate, job security should be offered to improve 
compliance, particularly in cases of severe infections, or in 
specialized or more renowned hospitals.
This pandemic has revealed several significant inadequa‑
cies of healthcare systems worldwide. The impact that this virus 
has had on the morbidity and mortality of healthcare personnel 
worldwide is a known and concerning fact. Studies performed 
in China, Italy, Spain and the United States have demonstrated 
that between 4‑32% of healthcare personnel are infected, with 
a mortality rate of 3% (42,43,44). Furthermore, meta‑analyses 
have indicated a high prevalence of anxiety (45%), depres‑
sion (38%), acute stress (31%), burnout (29%) and post‑traumatic 
stress (19%) among healthcare personnel (45,46).
Notably, Mexico is the country with the highest numbers 
of COVID‑19‑related deaths amongst healthcare workers. Of 
the ~7,000 health professionals worldwide who have lost their 
lives to Covid‑19, ≥1,320 were registered in Mexico, according 
to a report by Amnesty International (47).
Another relevant aspect is the substantial toll this pandemic 
has had on the global economy, with greater repercussions in 
countries that traditionally have weaker economies, and the 
severe and negative impacts it is having on the limited provi‑
sions available in these countries.
Finally, conducting a review of the accepted proto‑
cols (48,49) for the management of patients infected with 
COVID‑19, several drugs, including antineoplastic, immu‑
nomodulatory, antimalarial, non‑steroidal anti‑inflammatory 
drugs, antivirals, antimitotics, interferons, vitamins, antibiotics, 
anticoagulants, antineoplastic agents and steroids, exhibit one 
common feature, namely that they are generally being used 
for patients with complications; that is, where the pathogenic 
process has been given the opportunity to progress to affect 
multiple systems, which may at least partly explain the discrep‑
ancies in the results amongst studies. In addition to the effects 
of nitazoxanide against viral replication, its administration in 
experimental animals (12) has been shown to inhibit the cyto‑
kine storm caused by the dysregulation of the immune system, 
which in‑turn normally leads to multiple organ dysfunction 
syndrome and a high mortality rate in critical patients. The 
advantage of this drug is that it has a good biological profile 
with minimal side‑effects in a low percentage of patients, and 
it can be administered in individuals as young as 1 years of 
age, as well as in adults and even pregnant women. Ivermectin, 
an antiparasitic originally for developed for veterinary use, 
has recently become a drug of increased interest with regard 
to COVID‑19; however, it cannot be prescribed to children 
or pregnant women (50), and concentrations required for the 
inhibition of SARS‑CoV‑2 are not realistically attainable safely 
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in humans (51). By contrast, nitazoxanide is safe and effective 
at a wide range of doses, and is affordable and easily available 
in several countries and different healthcare institutions.
The present study has some limitations, including the fact 
that the viral load was not measured, and that this was not a 
randomized study. However, waiting for a final study that may 
establish the most efficient early‑stage treatment within a certain 
period of time is not realistic, as this may mean the possible 
further deaths of hundreds of colleagues, an unaffordable cost.
In conclusion, the results of the present study are promising 
and demonstrate that nitazoxanide administration may be a 
useful early intervention against SARS‑CoV‑2 to avoid complica‑
tions, reducing the institutional and social viral spread and thus, 
mortality. It is still undetermined whether a large‑scale intervention 
in families or communities by prescribing nitazoxanide will mark‑
edly reduce the spread of SARS‑CoV‑2. Thus, it is recommended 
that prescribing nitazoxanide for use against SARS‑CoV‑2 should 
be taken into consideration; perhaps, if it is prescribed at a suffi‑
ciently early stage, it may convert a potentially fatal infection into 
an ambulatory and curable disease. Hospitals could track, over a 
brief time period, the possible effects of nitazoxanide, contrasting 
the spread and outcomes of healthcare workers treated with this 
drug against those that did not receive it previously.
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